When To Consider Pharmacogenomic Testing In SSRI Non-Response

PGx Testing to Support SSRI Treatment

Selective serotonin reuptake inhibitors remain first-line treatment for depression and anxiety disorders in UK practice. However, a substantial proportion of patients fail to achieve remission after the first antidepressant trial. Repeated switching, dose escalation, and augmentation are common.

Pharmacogenomic testing is increasingly discussed in this context. The practical question for clinicians is not whether pharmacogenomics is scientifically interesting, but when it is clinically useful.

At the same time, pharmacogenomics is gaining strategic attention within NHS long-term planning, particularly in mental health and ADHD prescribing. Understanding where testing genuinely adds value is therefore important both clinically and systemically.

Defining Non-Response

Before considering testing, it is essential to clarify what constitutes non-response.

True non-response generally requires:

• Adequate dose

• Adequate duration, typically six to eight weeks

• Reasonable adherence

Partial response, early intolerance, and discontinuation due to side effects represent distinct scenarios. Pharmacogenomic testing is more likely to be informative in some of these than others.

The Role Of CYP2C19 And CYP2D6 In SSRI Treatment

Many commonly prescribed SSRIs depend on CYP enzymes for metabolism.

• Citalopram is metabolised primarily by CYP2C19
• Sertraline is metabolised primarily by CYP2C19, with additional contributions from CYP2B6, CYP2D6 and CYP3A4
• Paroxetine is largely metabolised by CYP2D6

Genetic variation in these enzymes alters systemic exposure.

A CYP2C19 poor metaboliser taking citalopram may experience higher plasma concentrations at standard doses, increasing the risk of dose-related adverse effects. A CYP2C19 ultrarapid metaboliser may have reduced exposure and apparent inefficacy.

In such cases, non-response or intolerance may reflect altered pharmacokinetics rather than failure of the drug’s pharmacodynamic mechanism.

When Testing Is Most Clinically Useful

Pharmacogenomic testing may be particularly helpful in the following scenarios.

Repeated Antidepressant Failure

Where two or more adequate SSRI trials have failed, genotype information may clarify whether altered drug exposure contributed to poor response.

Early Dose-Limiting Intolerance

Patients who develop significant adverse effects at low or standard doses may have elevated plasma concentrations due to reduced metabolism.

Apparent Non-Response At Standard Doses

In ultrarapid metabolisers, standard dosing may not achieve sufficient therapeutic exposure.

Cardiac Risk With Citalopram

Because citalopram carries dose-dependent QT prolongation risk, CYP2C19 poor metaboliser status may be relevant in patients with cardiac comorbidity or concomitant QT-prolonging medication.

Complex Polypharmacy

Concomitant CYP inhibitors can functionally reduce enzyme activity, increasing exposure even in patients with normal genotype. In these cases, pharmacogenomic data may help interpret tolerability patterns.

When Testing Is Less Likely To Change Management

Pharmacogenomic testing is less likely to alter decision-making when:

• The patient has not yet completed an adequate therapeutic trial

• Non-adherence is suspected

• Psychosocial factors predominate

• The medication in question is not strongly CYP-dependent

Testing does not replace careful psychiatric assessment or longitudinal review.

Emerging Trends In Mental Health Pharmacogenomics

Mental health and ADHD prescribing are increasingly recognised as high-impact areas for pharmacogenomic implementation. Compared with many other specialties, psychiatry involves:

• High prescribing volume

• Recurrent trial-and-error switching

• Significant adverse effect burden

• Long treatment durations

These features make antidepressant pharmacogenomics particularly attractive from both a patient and system perspective.

At the policy level, there is growing interest in targeted panels focused on well-characterised CYP genes rather than broad genomic testing. CYP2C19 and CYP2D6, which influence many antidepressants, are frequently cited as early implementation candidates.

There is also increasing recognition that allele frequencies vary across ethnic groups, including within diverse UK populations. Panels validated predominantly in European cohorts may not fully reflect metabolic variation seen in South Asian, African, or other ancestries. This consideration is likely to become increasingly relevant in commissioning discussions.

For clinicians in private practice, this evolving landscape reinforces the importance of using pharmacogenomic testing selectively, transparently, and in a way that aligns with established evidence rather than marketing claims.

A Practical Clinical Approach

In practice, a structured approach may be helpful.

1. Confirm dose, duration, and adherence.

2. Review side-effect profile and timing.

3. Assess for drug-drug interactions.

4. Consider pharmacogenomic testing if altered exposure is suspected.

Where genotype reveals reduced metabolism, dose reduction or alternative SSRI selection may be appropriate. Where ultrarapid metabolism is identified, selecting a drug less dependent on that pathway may be reasonable.

Pharmacogenomics informs exposure. It does not determine psychological resilience, illness severity, or social determinants of recovery.

Frequently Asked Questions

Should All Patients Be Tested Before Starting An SSRI

Routine pre-emptive testing is not currently standard in UK practice. Targeted testing after treatment difficulty remains the most common approach.

Does Pharmacogenomic Testing Predict Which SSRI Will Work Best

Testing predicts drug exposure rather than intrinsic antidepressant efficacy. It may reduce adverse effects or avoid subtherapeutic dosing, but it does not determine which medication will be psychologically superior.

Is Pharmacogenomic Testing Becoming Standard In The NHS

There is increasing strategic interest in pharmacogenomics within UK healthcare planning, particularly in mental health and cardiovascular medicine. However, routine antidepressant testing is not yet universally commissioned. Implementation is evolving and remains targeted.

Closing Thoughts

Pharmacogenomic testing is most useful in SSRI non-response when altered drug exposure is a plausible explanation for treatment failure or intolerance. It is less helpful in early treatment or where psychosocial factors predominate.

As interest in mental health pharmacogenomics grows, clinicians should remain grounded in evidence. Used selectively and thoughtfully, genotype-informed prescribing may reduce unnecessary switching and improve tolerability. Used indiscriminately, it risks adding complexity without clear clinical benefit.

The decision to test should therefore be deliberate, case-based, and integrated into a broader clinical framework.